bims-livmat Biomed News
on Living materials
Issue of 2026–11–15
five papers selected by
Sara Trujillo Muñoz, Leibniz-Institut für Neue Materialien



  1. MRS Commun. 2026 ;16(5): 1481-1491
       Abstract: Fungal bioelectricity has promising potential for biosensing in engineered living materials, but its nature remains unclear. We use a custom microelectrode array to record the extracellular electrical activity of mycelium, along with optical tracking and impedance measurements. Measurements across three mycelial growth experiments, along with a sterile control and biocide treatment, show that spontaneous signals coincide with mycelial growth. The signals contained transient spikes with rate and amplitude distributions dependent on growth. The measurements revealed distinct rise-and-fall patterns of electrical activity as mycelium overgrew the electrodes. These results establish an initial basis for future studies and living-material applications.
    Graphical abstract:
    Supplementary Information: The online version contains supplementary material available at https://doi.org/10.1557/s43579-026-01041-7.
    Keywords:  Bioelectronic; Biomaterial; Microelectronics; Responsive; Sensor
    DOI:  https://doi.org/10.1557/s43579-026-01041-7
  2. Int J Mol Sci. 2026 Nov 07. pii: 9977. [Epub ahead of print]27(21):
      Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are established treatments for obesity and type 2 diabetes mellitus, but gastrointestinal barriers constrain oral delivery of peptide therapeutics. Genetically engineered microorganisms have been investigated as intestinal sources of GLP-1-related therapeutic molecules. These platforms produce GLP-1 or GLP-1-derived peptides, express modified GLP-1RAs or fusion proteins, or release effectors that stimulate endogenous GLP-1 secretion. Preclinical studies have reported improvements in glycemic measures and, in some models, reductions in body weight or weight gain. However, recombinant product expression and treatment-associated effects are more consistently demonstrated than exposure to intact biologically active products in vivo, receptor or pathway dependence, and the contribution of the engineered construct relative to the microbial chassis. Proteolysis, mucus interactions, restricted epithelial permeability, and receptor localization constrain access to intestinal and systemic targets. This review critically evaluates the preclinical evidence for GLP-1-oriented engineered microorganisms, with emphasis on intestinal target accessibility, local and systemic mechanisms, microbial chassis and genetic design, and the safety, manufacturing, and regulatory requirements for clinical translation.
    Keywords:  GLP-1 receptor agonists; engineered microorganisms; enteroendocrine signaling; glucagon-like peptide-1; intestinal delivery; living therapeutics; obesity; type 2 diabetes mellitus
    DOI:  https://doi.org/10.3390/ijms27219977
  3. Front Genet. 2026 ;17 2008399
      Living genetically engineered microorganisms (GEMs) are increasingly used in consumer products and environmental applications, yet U.S. biotechnology regulation relies on statutes that predate their development or are designed for other types of products. This article examines oversight of living GEMs through 3 case studies of consumer and environmental GEM applications. Across these cases, federal premarket review was very limited or absent because oversight depended on distinctions such as the type of modification, the developer's product classification, or marketing claims. These regulatory pathways may not always align uniformly with the potential health and environmental risk profiles. While not all GEMs require the same level of oversight, current regulatory gaps have allowed for the large-scale, open release of these GEMs without substantial federal oversight. The article recommends baseline federal notification, changes to statutes or regulations to strengthen regulatory foundations, greater transparency, independent evaluation, and post-market monitoring, while also preserving efficient pathways for lower-risk applications. These enhancements to the regulation of GEMs will become increasingly important for effective risk governance as consumer and environmental products incorporate advanced synthetic biology approaches.
    Keywords:  biotechnology; genetically engineered microbes; governance; policy recommendations; regulation
    DOI:  https://doi.org/10.3389/fgene.2026.2008399
  4. Front Gastroenterol (Lausanne). 2026 ;5 1980209
      Mucosal vaccination is attracting renewed interest because many clinically relevant pathogens first encounter the host at gastrointestinal or respiratory surfaces, whereas most established vaccines are administered parenterally and are optimized primarily to induce systemic immunity. Engineered probiotics are emerging as living antigen-delivery vectors that may combine mucosal delivery, transient biological persistence, microbial immune signals, and programmable antigen presentation within a single platform. This strategy is particularly relevant to gastrointestinal vaccination, where access to gut-associated lymphoid tissue (GALT) may support local secretory IgA together with systemic responses. SARS-CoV-2 provides an informative experimental bridge because, despite its dominant respiratory manifestations, it can involve intestinal epithelial cells and gastrointestinal mucosal immunity. Using the pAIDA-Escherichia coli Nissle 1917 (EcN) system as a bounded proof of concept, this Perspective defines an integrated translational framework linking GALT-directed immune priming, effective mucosal antigen dose, genetic stability, chassis de-risking, biocontainment, manufacturing, potency, and post-administration clearance. We explicitly distinguish antigen delivery and immunogenicity from functional immunity, protection, and clinical efficacy, and identify the experiments required to advance probiotic-vectored mucosal vaccines toward clinically testable products.
    Keywords:  Escherichia coli Nissle 1917; GALT; engineered probiotics; intranasal vaccine; mucosal vaccination; oral vaccine; pAIDA; secretory IgA
    DOI:  https://doi.org/10.3389/fgstr.2026.1980209
  5. Cell Rep Methods. 2026 Nov 11. pii: S2667-2375(26)00363-2. [Epub ahead of print] 101662
      Biopharmaceuticals, including antimicrobial peptides and engineered protein-based vaccines, represent key products of the biotechnology sector. However, their reliance on large-scale manufacturing and cold-chain logistics limits deployment in field and resource-limited settings. To address this gap, we developed SporeBot, a platform that exploits the intrinsic stability of Bacillus subtilis spores for versatile and on-demand biopharmaceutical production. The platform comprises polymeric microcapsules that encapsulate engineered spores. These spores exhibit robust stability, retaining engineered functionality under harsh conditions and extended storage. Upon activation, germinated cells secrete the target proteins, which diffuse across a polymeric mesh that physically separates the cellular factory from the secreted product. We validate this platform through the production and functional testing of antimicrobial peptides and vaccine antigens. Our approach resolves key manufacturing and distribution constraints of protein therapeutics and offers a deployable solution for on-demand biomanufacturing in both developed and resource-limited settings.
    Keywords:  CP: biotechnology; CP: microbiology; biopharmaceuticals; on-demand biomanufacturing; spores; synthetic biology
    DOI:  https://doi.org/10.1016/j.crmeth.2026.101662